There are 1105 resources available
227P - Adjuvant tislelizumab plus TACE in resected high-risk hepatocellular carcinoma (ATTACK): Preliminary analysis of a prospective cohort study
Presenter: Jiao Liu
Session: Poster Display session
Resources:
Abstract
228P - Arsenic sulfide enhances the therapeutic effect of hepatocellular carcinoma immunotherapy through STAT3-THBS1/CD47 pathway
Presenter: Ting Kang
Session: Poster Display session
Resources:
Abstract
229P - The efficacy and safety of avatrombopag in the treatment of thrombocytopenia secondary to targeted and immunotherapy in hepatocellular carcinoma
Presenter: Xuehui Peng
Session: Poster Display session
Resources:
Abstract
230P - Individual-specific edge-network of gene interactions identified a robust prognostic score in hepatocellular carcinoma patients
Presenter: Ke Xu
Session: Poster Display session
Resources:
Abstract
231P - CT image-based artificial intelligence quantification of intratumoral heterogeneity for predicting treatment response to immunotherapy combined with anti-angiogenic drugs in hepatocellular carcinoma
Presenter: Zhi-Cheng Jin
Session: Poster Display session
Resources:
Abstract
232P - Selective internal radiation therapy with Yttrium-90 (Y-90) resin microspheres for unresectable hepatocellular carcinoma: Experience of a single center in China
Presenter: Xiaobin Feng
Session: Poster Display session
Resources:
Abstract
233P - Association of circulating inflammatory marker ISG15 with clinical factors and survival in patients with liver cancer
Presenter: Winnie Yeo
Session: Poster Display session
Resources:
Abstract
234P - Mechanism of acinetobacter baumannii promoting gastric cancer metastasis by enhancing NAD metabolism
Presenter: Yan Yang
Session: Poster Display session
Resources:
Abstract
235P - Combined atezolizumab and bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma: A single center experience
Presenter: Abdallah Khalil
Session: Poster Display session
Resources:
Abstract
236P - Characteristics and prognosis of primary and acquired resistance to immune checkpoint inhibitors combination treatment in unresectable hepatocellular carcinoma
Presenter: Xiangqi Chen
Session: Poster Display session
Resources:
Abstract